|
|
GMAT Club Daily Prep
Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.
Customized
for You
Track
Your Progress
Practice
Pays
Not interested in getting valuable practice questions and articles delivered to your email? No problem, unsubscribe here.
27 Jun 2022, 21:00
Kudos
Bookmarks
Question 1
E
Be sure to select an answer first to save it in the Error Log before revealing the correct answer (OA)!
Difficulty:
5%
(low)
Question Stats:
84% (02:10) correct
16%
(01:57) wrong
based on 134
sessions
History
Date
Time
Result
Not Attempted Yet
Question 2
A
Be sure to select an answer first to save it in the Error Log before revealing the correct answer (OA)!
Difficulty:
35%
(medium)
Question Stats:
53% (00:41) correct 47%
(00:51) wrong
based on 122
sessions
History
Date
Time
Result
Not Attempted Yet
Question 3
C
Be sure to select an answer first to save it in the Error Log before revealing the correct answer (OA)!
Difficulty:
15%
(low)
Question Stats:
72% (00:48) correct 28%
(00:49) wrong
based on 117
sessions
History
Date
Time
Result
Not Attempted Yet
Question 4
C
Be sure to select an answer first to save it in the Error Log before revealing the correct answer (OA)!
Difficulty:
35%
(medium)
Question Stats:
63% (00:54) correct 37%
(01:05) wrong
based on 120
sessions
History
Date
Time
Result
Not Attempted Yet
Question 5
A
Be sure to select an answer first to save it in the Error Log before revealing the correct answer (OA)!
Difficulty:
55%
(hard)
Question Stats:
58% (01:14) correct 42%
(01:11) wrong
based on 115
sessions
History
Date
Time
Result
Not Attempted Yet
Widespread media coverage tells us today of a new drug that “halts” Alzheimer’s symptoms “for three years.” The news is based on a press release issued yesterday that highlighted positive early results of research into the use of intravenous immunoglobulin to treat Alzheimer’s disease.
Intravenous immunoglobulin (IVIG) is a medication made by harvesting antibodies from donated blood. It is currently used to treat severe forms of infection and a number of autoimmune conditions (where the immune system attacks healthy tissue).
The idea behind using IVIG to treat Alzheimer’s disease is that it could encourage the immune system to “attack” abnormal clumps of protein (amyloid plaques) that can develop in the brains of people with Alzheimer’s disease.
Some media coverage of the press release was inaccurate. The Daily Express tells us there is a “pill to beat Alzheimer’s” when IVIG is actually given by injection into a blood vessel. The Daily Mail describes it as a “new vaccine,” which is technically incorrect as it implies only one injection needs to be given when in fact IVIG was injected every two weeks.
Once past the somewhat misleading headlines, most coverage does mention that it may be 10 years before this drug can be available, if it passes further scrutiny. IVIG can also be very expensive to manufacture, so this may limit its availability through the national health service.
Limited conclusions can be drawn from this research as it is in its early stage, was conducted on a small number of people, and was not peer-reviewed. Larger studies that compare IVIG to other existing treatments for Alzheimer’s disease are required to determine how safe and effective the drug is.
Intravenous immunoglobulin (IVIG) is a medication made by harvesting antibodies from donated blood. It is currently used to treat severe forms of infection and a number of autoimmune conditions (where the immune system attacks healthy tissue).
The idea behind using IVIG to treat Alzheimer’s disease is that it could encourage the immune system to “attack” abnormal clumps of protein (amyloid plaques) that can develop in the brains of people with Alzheimer’s disease.
Some media coverage of the press release was inaccurate. The Daily Express tells us there is a “pill to beat Alzheimer’s” when IVIG is actually given by injection into a blood vessel. The Daily Mail describes it as a “new vaccine,” which is technically incorrect as it implies only one injection needs to be given when in fact IVIG was injected every two weeks.
Once past the somewhat misleading headlines, most coverage does mention that it may be 10 years before this drug can be available, if it passes further scrutiny. IVIG can also be very expensive to manufacture, so this may limit its availability through the national health service.
Limited conclusions can be drawn from this research as it is in its early stage, was conducted on a small number of people, and was not peer-reviewed. Larger studies that compare IVIG to other existing treatments for Alzheimer’s disease are required to determine how safe and effective the drug is.
1. Which of the following would be the most fitting title to this passage?
a. New Drug to Combat Alzheimer’s to Be Released on the Market
b. Alzheimer’s Cure a Complete Fabrication
c. Miracle Pill for Alzheimer’s Has Patients Hopeful
d. Weakened Immune Systems of Patients to Blame for Alzheimer’s
e. Reports of Potential Breakthrough Alzheimer’s Treatment Both Premature and Misinformed
a. New Drug to Combat Alzheimer’s to Be Released on the Market
b. Alzheimer’s Cure a Complete Fabrication
c. Miracle Pill for Alzheimer’s Has Patients Hopeful
d. Weakened Immune Systems of Patients to Blame for Alzheimer’s
e. Reports of Potential Breakthrough Alzheimer’s Treatment Both Premature and Misinformed
2. The author’s attitude about the medication being studied to treat Alzheimer’s would be best described as:
a. skeptical
b. ambivalent
c. stoic
d. enthusiastic
e. cantankerous
a. skeptical
b. ambivalent
c. stoic
d. enthusiastic
e. cantankerous
3. According to the passage, all of the following are true about IVIG EXCEPT:
a. IVIG will be administered by injection.
b. IVIG will encourage the immune system to fight proteins in the brain.
c. IVIG can be defined as a vaccine.
d. IVIG may not be available for 10 years or more.
e. IVIG may not be cost-efficient to produce.
a. IVIG will be administered by injection.
b. IVIG will encourage the immune system to fight proteins in the brain.
c. IVIG can be defined as a vaccine.
d. IVIG may not be available for 10 years or more.
e. IVIG may not be cost-efficient to produce.
4. Which of the following would best describe the purpose of the fourth paragraph?
a. It refutes an argument presented by others in the medical field.
b. It provides an objective approach that has been expounded upon by many.
c. It serves to introduce the author’s misgivings about the media.
d. It denounces the accuracy of a study.
e. It combines the background information with the opinions of different medical professionals.
a. It refutes an argument presented by others in the medical field.
b. It provides an objective approach that has been expounded upon by many.
c. It serves to introduce the author’s misgivings about the media.
d. It denounces the accuracy of a study.
e. It combines the background information with the opinions of different medical professionals.
5. Which of the following statements is the author most likely to agree with?
a. Exciting new medical breakthroughs regarding the treatment of Alzheimer’s could be around the corner, but it is unknown how long the road ahead is.
b. The use of IVIG should be introduced to senile mice before it is used to treat people.
c. Research dedicated to a drug that doesn’t attack abnormal clumps but rather coaxes them should be paramount for any scientists involved in this study.
d. The media have a tendency to deliver misleading information to the public because sensationalism sells.
e. A national healthcare system could introduce medications to people with Alzheimer’s who couldn’t afford it otherwise.
a. Exciting new medical breakthroughs regarding the treatment of Alzheimer’s could be around the corner, but it is unknown how long the road ahead is.
b. The use of IVIG should be introduced to senile mice before it is used to treat people.
c. Research dedicated to a drug that doesn’t attack abnormal clumps but rather coaxes them should be paramount for any scientists involved in this study.
d. The media have a tendency to deliver misleading information to the public because sensationalism sells.
e. A national healthcare system could introduce medications to people with Alzheimer’s who couldn’t afford it otherwise.
RC Butler 2022 - Practice Two RC Passages Everyday.
Passage # 257 Date: 28-Jun-2022
This question is a part of RC Butler 2022. Click here for Details
Passage # 257 Date: 28-Jun-2022
This question is a part of RC Butler 2022. Click here for Details
04 Oct 2022, 00:50
Kudos
Bookmarks
aarav293
Official Explanation
3. According to the passage, all of the following are true about IVIG EXCEPT:
Difficulty Level: 600
Explanation
In the fourth paragraph, the author states that although a news source called it one, a vaccine would technically only be administered once, and this drug will need to be delivered every two weeks. The drug will be administered by injection, so choice a is incorrect. The answer is not choice b. The author reports that IVIG will encourage the immune system to fight proteins in the brain of Alzheimer’s patients. The answer is not choice d. The author reports that IVIG may not be available for 10 or more years. The answer is not choice e. The author states that IVIG may be expensive to manufacture.
Answer: C
Difficulty Level: 600
Explanation
In the fourth paragraph, the author states that although a news source called it one, a vaccine would technically only be administered once, and this drug will need to be delivered every two weeks. The drug will be administered by injection, so choice a is incorrect. The answer is not choice b. The author reports that IVIG will encourage the immune system to fight proteins in the brain of Alzheimer’s patients. The answer is not choice d. The author reports that IVIG may not be available for 10 or more years. The answer is not choice e. The author states that IVIG may be expensive to manufacture.
Answer: C
